Benzinga · Oct 6, 2026
Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer
Kairos Pharma evaluates ENV-105 with apalutamide in a Phase 2 trial targeting drug-resistant metastatic prostate cancer patients.
KA
AMEX · KAPA
Kairos Pharma, Ltd.
Healthcare · Biotechnology
$0.54
Down-$0.03 (-5.65%)
Updated Oct 23, 2026, 10:45 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 16.86M
- P/E ratio
- -3.24
- Dividend yield
- 0.00%
- 52-week range
- $0.22 – $2.16
- Volume
- 84.1K
- Avg. volume
- 529.54K
Price performance · KAPA
KAPA price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 22, 2026
KAPA closed at $0.54 after 21 trading sessions, down 69.27% for the selected period.
- Last close
- $0.54
- Period change
- -69.27%
- Period low
- $0.54
- Period high
- $1.77
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 22, 2026 | $0.5852 | $0.6001 | $0.5432 | $0.544 | 84.1K |
| Oct 21, 2026 | $0.5662 | $0.6171 | $0.565 | $0.5766 | 165.44K |
| Oct 20, 2026 | $0.5575 | $0.6029 | $0.5302 | $0.5837 | 153.53K |
| Oct 19, 2026 | $0.6242 | $0.628 | $0.5215 | $0.5701 | 233.83K |
| Oct 16, 2026 | $0.6915 | $0.6915 | $0.6007 | $0.6013 | 134.53K |
| Oct 15, 2026 | $0.721 | $0.7315 | $0.6563 | $0.6706 | 253.33K |
| Oct 14, 2026 | $0.8038 | $0.8038 | $0.7108 | $0.743 | 285.97K |
| Oct 13, 2026 | $0.8315 | $0.8388 | $0.7834 | $0.8287 | 156.52K |
| Oct 12, 2026 | $0.8145 | $0.8389 | $0.74 | $0.832 | 251.09K |
| Oct 9, 2026 | $0.911 | $1.0039 | $0.7827 | $0.8103 | 640.49K |
| Oct 8, 2026 | $0.93 | $1.25 | $0.915 | $0.9595 | 5.82M |
| Oct 7, 2026 | $1.09 | $1.1399 | $0.848 | $0.87 | 1.1M |
| Oct 6, 2026 | $1.59 | $2.16 | $1.06 | $1.15 | 9.94M |
| Oct 5, 2026 | $1.55 | $1.59 | $1.52 | $1.55 | 19.58K |
| Oct 2, 2026 | $1.61 | $1.6199 | $1.535 | $1.56 | 25.76K |
| Oct 1, 2026 | $1.59 | $1.65 | $1.47 | $1.56 | 79.13K |
| Sep 30, 2026 | $1.71 | $1.78 | $1.60 | $1.64 | 99.47K |
| Sep 29, 2026 | $1.68 | $1.7552 | $1.64 | $1.66 | 53.28K |
| Sep 28, 2026 | $1.74 | $1.798 | $1.6503 | $1.68 | 53.5K |
| Sep 25, 2026 | $1.77 | $1.7799 | $1.72 | $1.72 | 42.32K |
| Sep 24, 2026 | $1.70 | $1.82 | $1.695 | $1.77 | 300.91K |
Latest KAPA news
The latest Smart Investors Daily articles mentioning KAPA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
KAPA research
Overview
Company profile and research snapshot.
Company profile
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 19, 2025 | D. Boral Capital | Buy | — |
| Nov 4, 2025 | D. Boral Capital | Buy | — |
| Oct 20, 2025 | D. Boral Capital | Buy | — |
| Oct 7, 2025 | D. Boral Capital | Buy | — |
| Sep 19, 2025 | D. Boral Capital | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 6, 2026
Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
LOS ANGELES, October 06, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim analysis demonstrated a statistically significant difference in progression-free survival (PFS) between all
Yahoo · Sep 23, 2026
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
LOS ANGELES, September 23, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick, President and Chief Scientific Officer, will both present and moderate a discussion in person at the 24th Annual Discovery on Target Drug Discovery Conference. The conference is being held on Sept. 28 to Oct. 1 at the Sheraton Boston Hotel with sessions available on demand on the conference’s website.
Yahoo · Sep 9, 2026
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
LOS ANGELES, September 09, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
